Sep. 18, 2021

RRx-001

surprisingly well-tolerated clinical molecule Ph. III candidate in SCLC (4 mg IV QW) from aerospace compound phenotypic screen J. Med. Chem., May 27, 2021 EpicentRx Inc., La Jolla, CA

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in